David A Williams MD

Pediatric Hematology & Oncology•Boston, MA

Leland Fikes Professor of Pediatrics, Boston Children's Hospital

Join to View Full Profile

300 Longwood AveKarp 8Boston, MA 02115
Phone+1 617-919-2697
Fax+1 617-730-0934

Summary

Chief Scientific Officer and SVP for Research; Chief of Hematology/Oncology, Boston Children's Hospital

Education & Training

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1982 - 1987
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1979 - 1982
Indiana University School of MedicineClass of 1979

Certifications & Licensure

MA State Medical License 1982 - 2027
OH State Medical License 1980 - 2009
IN State Medical License 1979 - 2003
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

Elected Member Institute of Medicine, 2002
Elected Member The American Society for Clinical Investigation, 1993
Super Doctor SuperDoctors.com
Fellow (FACC) American College of Cardiology
Join now to see all

Clinical Trials

Multicenter Phase II Trial-Hematopoietic Stem Cell Transplantation for Treatment of Patients With FA Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine Start of enrollment: 2009 Apr 01
Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 1, Phase 2
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD) Start of enrollment: 2013 Aug 21
Completed
Phase 2, Phase 3
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease Start of enrollment: 2015 Oct 29
COMPLETED
PHASE1, PHASE2
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia Start of enrollment: 2016 Aug 01
Active, not recruiting
Not Applicable
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 with Low Dose Targeted Busulfan Conditioning Start of enrollment: 2018 Feb 26
RECRUITING
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

A novel high-titer, bifunctional lentiviral vector for autologous hematopoietic stem cell gene therapy of sickle cell disease.
Kevyn L Hart, Boya Liu, Devin Brown, Beatriz Campo-Fernandez, Kevin Tam
Molecular Therapy. Methods & Clinical Development. 2024-06-13
13 citations
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease.
Michael Spencer Chapman, Alyssa H Cull, Marioara F Ciuculescu, Erica B Esrick, Emily Mitchell
Nature Medicine. 2023-12-01
12 citations
Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
Roxane Labrosse, Julia I Chu, Myriam A Armant, John K Everett, Danilo Pellin
Blood. 2023-10-12

Abstracts/Posters

Investigation of Cell-Contact Dependent Alterations in Immune Synapse Formation between T Cells and BCP-ALL Cells
David A Williams, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcome of Hematopoietic Stem Cell Gene Therapy for Wiskott-Aldrich Syndrome
David A Williams, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Advancing the Treatment of Hemoglobinopathies: Gene Therapy for Beta Thalassemia and Sickle Cell Disease
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Gene Therapy Offers Huge Potential for Combating Disease, Doctors SayMay 31st, 2024